06/13/2022

NETRIS Pharma at the BIO International Convention 2022 starting TODAY

Reading : 2 min

Come and meet NETRIS Pharma at the BIO International Convention starting TODAY in San Diego (June 13-16).

We are proud to be part of the convention and of the largest international delegation with French Healthcare :

http://www.frenchhealthcare.fr

Check out our video below 🎥 :

 

 

Suggested articles

logo Nature article
08/30/2023

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min
Bio Boston 2023
05/16/2023

NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering NETRIN-1-based drug discovery and development, is confirming today that CEO and Founder Patrick Mehlen, and CFO Christophe Guichard, will be attending the Bio International Convention taking place June 5-8, 2023, in Boston, MS. Meet with us at the Partnering booth ! For any information, please send an email to christopheguichard@netrispharma.com

Reading : 1 min
logo1
03/29/2023

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m_FOLFIRINOX for first line patients with Locally Advanced Pancreatic Ductal Adenocarcinoma

Reading : 5 min